{"id":"NCT02918357","sponsor":"University of California, San Francisco","briefTitle":"Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence","officialTitle":"Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-09-15","primaryCompletion":"2017-09-21","completion":"2017-09-21","firstPosted":"2016-09-28","resultsPosted":"2019-12-02","lastUpdate":"2019-12-02"},"enrollment":385,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Ga-68 labeled PSMA-11 PET","otherNames":["Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED-CC","Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC","Ga-68 labeled HBED-CC PSMA"]}],"arms":[{"label":"Ga-68 labeled PSMA-11 PET","type":"EXPERIMENTAL"}],"summary":"The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.","primaryOutcome":{"measure":"Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation","timeFrame":"1 month","effectByArm":[{"arm":"Pet Positive (Per Patient)","deltaMin":0.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":385},"commonTop":[]}}